Optimizing dendritic cell-based immunotherapy for cancer

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 333-345

  Zhong, Hua ^b   Shurin, Michael R ^a,c   Han, Baohui ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Clinical Immunopathology   (United States)

Author keywords

Cancer; Clinical trials; Cytokines; Dendritic cells; Immune escape; Immunosuppression; Immunotherapy; Vaccine

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INFLUENZA MATRIX PEPTIDE; KEYHOLE LIMPET HEMOCYANIN; MELAN A; MELANOMA ANTIGEN 3; MELPHALAN; MONOPHENOL MONOOXYGENASE; PEPTIDE; PROTEIN BCL XL; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; B CELL LYMPHOMA; BREAST CARCINOGENESIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; DRUG EFFICACY; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; KIDNEY CARCINOMA; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VACCINATION;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 34250340833     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.333     Document Type: Review

References (92)

1. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. USA 92, 8078-8082 (1995).
2. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58 (1996).
3. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29, 371-380 (1996).
4. Engleman EG. Dendritic cells in the treatment of cancer. Biol. Blood Marrow Transplant. 2, 115-117 (1996).
5. Engleman EG. Dendritic cells: potential role in cancer therapy. Cytotechnology 25, 1-8 (1997).
6. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
7. Palucka AK, Laupeze B, Aspord C et al. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol. 560, 105-114 (2005).
8. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 106, 271-274 (2001).
9. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21, 873-886 (2003).
10. Chang DH, Dhodapkar MV. Dendritic cells and immunotherapy for cancer. Int. J. Hematol. 77, 439-443 (2003).
11. Svane IM, Soot ML, Buus S, Johnsen HE. Clinical application of dendritic cells in cancer vaccination therapy. Apmis 111, 818-834 (2003).
12. Vieweg J, Jackson A. Modulation of antitumor responses by dendritic cells. Springer Semin. Immunopathol. 26, 329-341 (2005).
13. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104, 2235-2246 (2004).
14. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
15. Soruri A, Zwirner J. Dendritic cells: limited potential in immunotherapy. Int. J. Biochem. Cell. Biol. 37, 241-245 (2005).
16. Fay JW, Palucka AK, Paczesny S et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55(10), 1209-1218 (2006).
17. Punt CJ, de Vries IJ, Mulders PF, Adema GJ, Figdor CG. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer]. Ned. Tijdschr. Geneeskd 143, 2408-2414 (1999).
18. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat. Med. 7, 761-765 (2001).
19. Schnurr M, Chen Q, Shin A et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105, 2465-2472 (2005).
20. Morse MA, Lyerly HK. Clinical applications of dendritic cell vaccines. Curr. Opin. Mol. Ther. 2, 20-28 (2000).
21. Shurin MR. Preparation of human dendritic cells for tumor vaccination. Methods Mol. Biol. 215, 437-462 (2003).
22. Jeras M, Bergant M, Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells - potential antigen-specific modulators of in vivo immune responses. Transpl. Immunol. 14, 231-244 (2005).
23. O'Neill D, Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 109, 1-18 (2005).
24. Grunebach F, Muller MR, Brossart P. New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol. Immunother. 54(6), 517-525 (2005).
25. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17, 163-169 (2005).
26. Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer 13, 779-795 (2006).
27. Esche C, Lokshin A, Shurin GV et al. Tumor's other immune targets: dendritic cells. J. Leukoc. Biol. 66, 336-344 (1999). • First study describing tumor-induced apoptosis of dendritic cells (DCs).
28. Tourkova IL, Shurin GV, Chatta GS et al. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J. Immunol. 175, 3045-3052 (2005).
29. Shurin MR, Gabrilovich DI. Regulation of dendritic cell system by tumor. Cancer Res. Ther. Cont. 11, 65-78 (2001).
30. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 170, 2817-2823 (2003).
31. Shurin MR, Shurin GV, Lokshin A et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25, 333-356 (2006).
32. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr. Pharm. Des. 11, 3485-3500 (2005).
33. Shurin MR, Chatta GS, Shurin GV. Aging and the dendritic cell system: implications for cancer. Crit. Rev. Oncol. Hematol. DOI:10.1016/j. critrevonc.2007.03.002 (2007) (Epub ahead of print).
34. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50, 507-529 (1999).
35. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005). •• Excellent review discussing DC immunobiology, the regulation of immune responses by DCs and its implication for designing novel or improved DC vaccines.
36. Byrne SN, Halliday GM. Dendritic cells: making progress with tumour regression? Immunol. Cell. Biol. 80, 520-530 (2002). •• Great review focusing on DC-tumor cell interaction and discussing the importance of this phenomenon in developing novel DC-based therapies.
37. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5, 7-10 (2004).
38. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 19, 6673-6679 (2000).
39. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417 (2002).
40. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199, 251-263 (2004).
41. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol. Immunother. 55(9), 1122-1131 (2005).
42. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5, 397-405 (2005).
43. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM, Katz DR. The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res. 63, 5143-5150 (2003).
44. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 65, 8065-8068 (2005).
45. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 114, 11-22 (2005).
46. Becker Y. Anticancer role of dendritic cells (DC) in human and experimental cancers - a review. Anticancer Res. 12, 511-520 (1992). • From the historical point of view, this great review should be appreciated by all readers.
47. Shurin GV, Ferris R, Tourkova IL et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174, 5490-5498 (2005).
48. Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383-1393. (2000).
49. Candido KA, Shimizu K, McLaughlin JC et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61, 228-236. (2001).
50. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 61, 7530-7535 (2001).
51. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107-116 (2003).
52. Ahmed SU, Okamoto M, Oshikawa T et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4. J. Immunother. 27, 432-441 (2004).
53. Yurkovetsky ZR, Shurin GV, Barry DA, Schuh AC, Shurin MR, Robbins PD. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J. Gene Med. 8, 129-137 (2006).
54. Pirtskhalaishvili G, Shurin GV, Gambotto A et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J. Immunol. 165, 1956-1964. (2000).
55. Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res. 59, 2802-2805 (1999).
56. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89, 2646-2654. (2000). •• Argues for the therapeutic efficacy of intratumoral delivery of DC vaccines in patients with different types of cancer.
57. Feijoo E, Alfaro C, Mazzolini G et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int. J. Cancer. 116(2), 275-281 (2005).
58. Mazzolini G, Alfaro C, Sangro B et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 23, 999-1010 (2005).
59. Chi KH, Liu SJ, Li CP et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28, 129-135 (2005).
60. Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther. 7, 1167-1170 (2000).
61. Yang R, Xu D, Zhang A, Gruber A. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int. J. Cancer. 94, 407-413 (2001).
62. Vanderheyde N, Aksoy E, Amraoui Z, Vandenabeele P, Goldman M, Willems F. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J. Immunol. 167, 3565-3569. (2001).
63. Sun J, Zhang J, Chen J, Chen H, Chew Y. In vitro study on the morphology of human blood dendritic cells and LPAK cells inducing apoptosis of the hepatoma cell line. Chin. Med. J. (Engl.) 114, 600-605. (2001).
64. Pirtskhalaishvili G, Shurin GV, Esche C et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J. Cancer 83, 506-513 (2000).
65. Pirtskhalaishvili G, Shurin GV, Esche C, Trump DL, Shurin MR. TNF-α protects dendritic cells from prostate cancer-induced apoptosis. Prostate Cancer Prostatic Dis. 4, 221-227 (2001).
66. Esche C, Shurin GV, Kirkwood JM et al. Tumor necrosis factor-α-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res. 7, 974s-979s. (2001).
67. Tourkova IL, Yurkovetsky ZR, Gambotto A et al. Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Rα and Bcl-2. J. Leukoc. Biol. 72, 1037-1045. (2002).
68. van Schooten WC, Strang G, Palathumpat V. Biological properties of dendritic cells: implications to their use in the treatment of cancer. Mol. Med. Today 3, 254-260 (1997).
69. Di Nicola M, Anichini A, Mortarini R, Bregni M, Parmiani G, Gianni AM. Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytokines Cell. Mol. Ther. 4, 265-273 (1998).
70. Kochman S, Bernard J. Antitumour immune response and cancer vaccination: the critical role of dendritic cells. Curr. Med. Res. Opin. 15, 321-326 (1999).
71. Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit. Rev. Oncog. 11, 1-17 (2000).
72. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273 (2000).
73. Jefford M, Maraskovsky E, Cebon J, Davis ID. The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343-353 (2001).
74. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit. Rev. Immunol. 21, 133-145 (2001).
75. Meidenbauer N, Andreesen R, Mackensen A. Dendritic cells for specific cancer immunotherapy. Biol. Chem. 382, 507-520 (2001).
76. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94, 805-818 (2002).
77. Slovin SF. Dendritic cell vaccines - hopeful or hopeless? Cancer Invest. 21, 969-970 (2003).
78. Conrad C Nestle FO. Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther. 5, 405-412 (2003). •• Outstanding and comprehensive review on the results of ongoing clinical trials utilizing DCs in patients with cancer.
79. Berger TG, Schultz ES. Dendritic cell-based immunotherapy. Curr. Top. Microbiol. Immunol. 276, 163-197 (2003).
80. Santini SM, Belardelli F. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines. Stem Cells 21, 495-505 (2003).
81. Nencioni A, Brossart P. Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22, 501-513 (2004).
82. Turtle CJ, Hart DN. Dendritic cells in tumor immunology and immunotherapy. Curr. Drug Targets 5, 17-39 (2004). •• Beautiful review with many interesting suggestions on how to improve DC vaccines for cancer therapy.
83. Farkas A, Conrad C, Tonel G et al. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy. Skin Pharmacol. Physiol. 19, 124-131 (2006).
84. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46, 82-87 (1998).
85. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1, 72-81 (1999).
86. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br. J. Haematol. 112, 874-887 (2001).
87. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp. Hematol. 29, 1247-1255 (2001).
88. Burdin N, Moingeon P. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens. Cell. Biol. Toxicol. 17, 67-75 (2001).
89. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr. Opin. Mol. Ther. 4, 452-458 (2002).
90. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. 13, 439-447 (2003).
91. Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 18, 235-243 (2004). •• Outstanding review with the focus on DC biology relevant to investigators who work in transitional research programs. Good overview of published and ongoing clinical trials providing the basis for a discussion of perspectives of DC vaccination.
92. Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North Am. 20, 689-710 (2006).